^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ifosfamide

    Company:
    Generic mfg.
    Drug class:
    Bifunctional alkylating agent
    Related drugs:
    21h
    Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States. (PubMed, Clin Lymphoma Myeloma Leuk)
    Our findings support the use of PD-1 blockade in HIV-cHL for the same indications as the general population with cHL.
    Clinical • Journal • Real-world evidence • Real-world
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • ifosfamide • etoposide IV • Adcetris (brentuximab vedotin)
    8d
    Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma. (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Chinese PLA General Hospital
    New P2 trial • IO biomarker
    |
    PD-1 (Programmed cell death 1)
    |
    carboplatin • gemcitabine • ifosfamide • etoposide IV • decitabine • pegylated liposomal doxorubicin • Adcetris (brentuximab vedotin) • Epidaza (chidamide)
    9d
    Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma (clinicaltrials.gov)
    P2, N=137, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Mar 2024
    Trial completion • Trial completion date • Combination therapy
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Xalkori (crizotinib) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • Adcetris (brentuximab vedotin) • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    13d
    Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2/3, N=210, Not yet recruiting, University of Birmingham | Trial completion date: Oct 2032 --> May 2033 | Initiation date: Oct 2023 --> May 2024 | Trial primary completion date: Oct 2030 --> May 2031
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • Zynlonta (loncastuximab tesirine-lpyl) • odronextamab (REGN1979)
    20d
    Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors (clinicaltrials.gov)
    P2, N=262, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Mar 2024 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    AFP (Alpha-fetoprotein)
    |
    carboplatin • cyclophosphamide • ifosfamide • etoposide IV
    21d
    OS2006: Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma (clinicaltrials.gov)
    P3, N=318, Active, not recruiting, UNICANCER | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    cisplatin • doxorubicin hydrochloride • ifosfamide • etoposide IV • zoledronic acid
    24d
    Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=49, Recruiting, Oslo University Hospital | Trial completion date: Sep 2034 --> Sep 2036 | Trial primary completion date: Sep 2024 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    doxorubicin hydrochloride • ifosfamide
    28d
    TOUCH: A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=97, Recruiting, Antengene Corporation | Trial primary completion date: Dec 2023 --> May 2024
    Trial primary completion date
    |
    carboplatin • gemcitabine • Tevimbra (tislelizumab) • ifosfamide • oxaliplatin • etoposide IV • Xpovio (selinexor)
    1m
    Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=80, Recruiting, Mayo Clinic | N=55 --> 80
    Enrollment change
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection
    1m
    Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. (PubMed, Lancet)
    Afami-cel treatment resulted in durable responses in heavily pre-treated patients with HLA-A*02 and MAGE-A4-expressing synovial sarcoma. This study shows that T-cell receptor therapy can be used to effectively target solid tumours and provides rationale to expand this approach to other solid malignancies.
    P2 data • Journal • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • MAGEA4 expression
    |
    ifosfamide • afamitresgene autoleucel (ADP-A2M4)
    1m
    Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
    |
    CD20 positive
    |
    carboplatin • Imbruvica (ibrutinib) • Rituxan (rituximab) • Bavencio (avelumab) • cyclophosphamide • ifosfamide • etoposide IV • utomilumab (PF-05082566)
    2ms
    Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or CCUS (clinicaltrials.gov)
    P2, N=55, Recruiting, Mayo Clinic | Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • dexamethasone injection
    2ms
    Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=35, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    ifosfamide • Hepacid (pegargiminase)
    2ms
    Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL (clinicaltrials.gov)
    P2, N=20, Recruiting, RenJi Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 positive
    |
    carboplatin • Rituxan (rituximab) • lenalidomide • ifosfamide • Brukinsa (zanubrutinib) • etoposide IV
    2ms
    Narlumosbartmab Combined With Neoadjuvant Chemotherapy in Bone-derived Malignancies With Osteolytic Lesions and Multinucleated Giant Cells (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Peking University People's Hospital
    New trial
    |
    cisplatin • doxorubicin hydrochloride • ifosfamide
    2ms
    Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    everolimus • temozolomide • doxorubicin hydrochloride • Votrient (pazopanib) • cyclophosphamide • ifosfamide • irinotecan • Torisel (temsirolimus) • vincristine • daunorubicin • ganitumab (AMG 479)
    2ms
    Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors (clinicaltrials.gov)
    P2, N=262, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2024 --> Mar 2024 | Trial primary completion date: Sep 2019 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    AFP (Alpha-fetoprotein)
    |
    carboplatin • cyclophosphamide • ifosfamide • etoposide IV
    2ms
    Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=35, Not yet recruiting, Washington University School of Medicine | Trial completion date: Nov 2027 --> Feb 2028 | Initiation date: Jan 2024 --> Apr 2024 | Trial primary completion date: Nov 2025 --> Feb 2026
    Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy
    |
    ifosfamide • Hepacid (pegargiminase)
    2ms
    Neuroprotective effects of daidzein against ifosfamide-induced neurotoxicity in male rats: role of selected inflammatory and apoptotic markers. (PubMed, J Med Life)
    Conversely, pre-treatment with DZN significantly reduced serum inflammatory markers and caspase-3 levels in tissue. The findings suggest that daidzein has anti-inflammatory and anti-apoptotic properties, potentially offering protection against IFO-induced neurotoxicity in rats.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • CASP3 (Caspase 3)
    |
    CASP3 elevation
    |
    ifosfamide
    2ms
    Auto Transplant for High Risk or Relapsed Solid or CNS Tumors (clinicaltrials.gov)
    P=N/A, N=44, Completed, Masonic Cancer Center, University of Minnesota | Recruiting --> Completed | N=20 --> 44
    Trial completion • Enrollment change
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CD34 (CD34 molecule)
    |
    LDH elevation • MYCN amplification • MYCN expression
    |
    carboplatin • paclitaxel • ifosfamide • etoposide IV • melphalan • thiotepa • busulfan
    2ms
    MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=148, Not yet recruiting, HRYZ Biotech Co.
    New P2 trial
    |
    doxorubicin hydrochloride • ifosfamide
    3ms
    A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=40, Recruiting, Hoffmann-La Roche | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    carboplatin • Rituxan (rituximab) • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)
    3ms
    Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • Polivy (polatuzumab vedotin-piiq)
    3ms
    Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (clinicaltrials.gov)
    P2/3, N=140, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Surgery
    |
    doxorubicin hydrochloride • Votrient (pazopanib) • cyclophosphamide • ifosfamide • daunorubicin
    3ms
    Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors (clinicaltrials.gov)
    P2, N=262, Active, not recruiting, Children's Oncology Group | Trial completion date: Dec 2023 --> Sep 2024
    Trial completion date
    |
    AFP (Alpha-fetoprotein)
    |
    carboplatin • cyclophosphamide • ifosfamide • etoposide IV
    3ms
    IRCI Gynae Sarcomas, High Grade Uterine Sarcoma (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: Dec 2023 --> May 2024
    Trial completion date • Surgery • Metastases
    |
    doxorubicin hydrochloride • Cabometyx (cabozantinib tablet) • ifosfamide
    3ms
    GETUG 13: Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors (clinicaltrials.gov)
    P3, N=263, Active, not recruiting, UNICANCER | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    AFP (Alpha-fetoprotein)
    |
    cisplatin • paclitaxel • ifosfamide • oxaliplatin • etoposide IV • bleomycin
    3ms
    Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Yonsei University
    New trial • Metastases
    |
    ifosfamide
    3ms
    OLYMPIA-4: A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=216, Recruiting, Regeneron Pharmaceuticals
    New P3 trial
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • ifosfamide • etoposide IV • odronextamab (REGN1979)
    3ms
    Anticarcinogenic Effects of Gold Nanoparticles and Metformin Against MCF-7 and A549 Cells. (PubMed, Biol Trace Elem Res)
    RT-PCR assays showed ifosfamide + metformin + gold nanoparticles significantly reduced the expression of BCL2, PI3K, Akt3, mTOR, Hsp60 and Hsp70 and increased the expression of TNF-α and Bax. The findings obtained in this study suggest that further studies should be conducted, and metformin and gold nanoparticles can be used in breast cancer and lung cancer treatments.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • mTOR (Mechanistic target of rapamycin kinase) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • HSPD1 (Heat Shock Protein Family D (Hsp60) Member 1) • PI3K (Phosphoinositide 3-kinases)
    |
    BCL2 expression • BAX expression
    |
    ifosfamide • metformin
    3ms
    NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) (clinicaltrials.gov)
    P1/2, N=139, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    doxorubicin hydrochloride • Votrient (pazopanib) • cyclophosphamide • ifosfamide • Xpovio (selinexor)
    3ms
    NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) (clinicaltrials.gov)
    P1/2, N=139, Not yet recruiting, St. Jude Children's Research Hospital
    New P1/2 trial
    |
    doxorubicin hydrochloride • Votrient (pazopanib) • cyclophosphamide • ifosfamide • Xpovio (selinexor)
    3ms
    Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients. (PubMed, Lung Cancer)
    Surgery was the first treatment in most patients (46 %) and 80 % were treated with polychemotherapies, showing longer progression free survival (PFS) with ifosfamide-based than with platinum-based regimens...This is the largest adult European cohort of this orphan tumor disease, showing epidemiologic and molecular features as well as relevant clinical data. Awareness to prevent misdiagnosis, fast contact to a specialized nation-wide center and referral to clinical studies are essential as long-term survival is rarely achieved with any of the current therapeutic regimes.
    Journal • IO biomarker
    |
    BRD4 (Bromodomain Containing 4) • NUTM1 (NUT Midline Carcinoma Family Member 1)
    |
    ifosfamide
    4ms
    High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors (clinicaltrials.gov)
    P2, N=64, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    CD34 (CD34 molecule)
    |
    carboplatin • gemcitabine • docetaxel • ifosfamide • etoposide IV • melphalan
    4ms
    Drug Screening Using IMD in Bladder Cancer (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Brigham and Women's Hospital
    New P1 trial
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • Bavencio (avelumab) • doxorubicin hydrochloride • Balversa (erdafitinib) • ifosfamide • vinblastine
    4ms
    Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma (clinicaltrials.gov)
    P2, N=40, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2024 --> Jan 2034 | Trial primary completion date: Jan 2024 --> Jan 2034
    Trial completion date • Trial primary completion date
    |
    carboplatin • ifosfamide • etoposide IV
    4ms
    EPCORE NHL-2: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (clinicaltrials.gov)
    P1/2, N=662, Recruiting, Genmab | Phase classification: P1b/2 --> P1/2
    Phase classification • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    carboplatin • gemcitabine • Rituxan (rituximab) • lenalidomide • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • vincristine • bendamustine • Epkinly (epcoritamab-bysp)
    4ms
    Adriamycin and Ifosfamide Combined With Sintilimab (clinicaltrials.gov)
    P2, N=176, Recruiting, Sun Yat-sen University | N=69 --> 176 | Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    Tyvyt (sintilimab) • doxorubicin hydrochloride • ifosfamide
    4ms
    MEGACEP: Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis (clinicaltrials.gov)
    P2, N=37, Recruiting, UNICANCER
    Trial completion date • Trial primary completion date
    |
    cisplatin • paclitaxel • ifosfamide
    4ms
    Initial chemotherapy for locally advanced and metastatic NUT carcinoma. (PubMed, J Thorac Oncol)
    There is a numerically higher ORR for ifosfamide-based therapy compared to platinum-based therapy, with limited durability. OS at 3 years is only 19%, and development of effective therapies is an urgent unmet need for this patient population.
    Journal • Metastases
    |
    BRD4 (Bromodomain Containing 4) • NUTM1 (NUT Midline Carcinoma Family Member 1)
    |
    ifosfamide
    5ms
    Analysis of treatment sequence and outcomes in patients with relapsed malignant peripheral nerve sheath tumors. (PubMed, Neurooncol Adv)
    Most patients (n = 42, 87.5%) received a combination of doxorubicin, ifosfamide, or etoposide as first-line chemotherapy. Salvage chemotherapy regimens and their TTP varied greatly, with irinotecan/temozolomide-based regimens having the longest average TTP (255.5 days, among 4 patients). Patients with advanced or metastatic MPNST often succumb to their disease despite multiple lines of therapy. These data may be used as comparative information in decision-making for future patients and clinical trials.
    Journal
    |
    NF1 (Neurofibromin 1)
    |
    temozolomide • doxorubicin hydrochloride • ifosfamide • etoposide IV • irinotecan
    5ms
    InPACT: International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) (clinicaltrials.gov)
    P3, N=200, Recruiting, Institute of Cancer Research, United Kingdom | Trial completion date: Aug 2025 --> May 2026
    Trial completion date
    |
    cisplatin • paclitaxel • ifosfamide